Avacta Group
Avacta Group is focused on the development and commercialization of novel cancer therapies and diagnostics based on its proprietary Affimer® platform, a novel class of biotherapeutics that are designed to target and modulate the function of specific proteins implicated in various diseases.Content by Avacta Group
Filter by
AllArticlesAudioEbooksEventsInfographicsNewsProductsSurveysDocumentsVideosVirtual EventsWebinars
Global distribution agreement with ABCAM plc to sell Avacta’s SARS-CoV-2 research ELISA Affimer reagents
| 2 min read
Affimer-based research assay launched alongside performance data published by Bruker
| 2 min read
Avacta to make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus
| 2 min read
Highly specific prototype test detects the virus spike protein at clinically relevant concentrations
| 3 min read
Second partnership to exploit the recently generated Affimer binders to the SARS-COV-2 virus in a high throughput COVID-19 antigen test
| 3 min read
Avacta successfully generates several highly specific Affimer reagents for COVID-19 antigen rapid test ahead of schedule as part of Cytiva partnership
| 2 min read
Partnership to develop and manufacture a rapid test for the COVID-19 coronavirus infection for population screening
| 2 min read
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits
| 3 min read
Page 1 of 1 - 8 Total Items
